Compare FRSX & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | INBS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 5.3M |
| IPO Year | 2017 | N/A |
| Metric | FRSX | INBS |
|---|---|---|
| Price | $1.74 | $6.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 573.9K | 40.1K |
| Earning Date | 03-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $452,000.00 | ★ $3,292,042.00 |
| Revenue This Year | N/A | $778.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.26 |
| 52 Week Low | $1.52 | $5.09 |
| 52 Week High | $18.41 | $27.50 |
| Indicator | FRSX | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 31.84 | 84.04 |
| Support Level | $1.52 | $0.54 |
| Resistance Level | $1.90 | $7.25 |
| Average True Range (ATR) | 0.11 | 0.37 |
| MACD | -0.03 | 0.70 |
| Stochastic Oscillator | 17.55 | 83.55 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.